GlassScriptPhysician profile
Alexander Friedman
NPI 1730621848
$4,536.41
in general payments reported to CMS, 2019-2025
28 companies · $49.23 in 2025
The $49.23 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $444 · 2022: $1,203 · 2023: $1,728 · 2024: $1,113 · 2025: $49.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,890.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $724.18 | 2021-2024 | |
| Lilly USA, LLC | $556.64 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $542.78 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $453.19 | 2022-2025 | |
| Glaxosmithkline, LLC. | $406.32 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $232.68 | 2022-2024 | Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $216.45 | 2023 | Quviviq |
| Pfizer INC. | $186.18 | 2022-2024 | |
| Mylan Specialty L.P. | $164.98 | 2023-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $134.47 | 2021-2024 | Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $120.87 | 2022 | |
| Sanofi-Aventis U.S. LLC | $117.81 | 2021-2023 | |
| Abbott Laboratories | $93.19 | 2022-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $83.11 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.37 | 2022-2024 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $74.79 | 2021-2024 | Eliquis, Camzyos |
| Radius Health, INC. | $70.15 | 2023 | Tymlos |
| Allergan, INC. | $45.34 | 2021-2022 | |
| Horizon Therapeutics Plc | $40.11 | 2022-2023 | Krystexxa |
| Viiv Healthcare Company | $29.36 | 2023-2024 | Apretude |
| Janssen Pharmaceuticals, INC | $26.45 | 2022 | |
| Myriad Women'S Health, INC. | $25.79 | 2023 | Myrisk |
| Smith+Nephew, INC. | $24.50 | 2025 | Grafix Pl, Stravix Pl |
| Sanofi Pasteur INC. | $22.50 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.74 | 2023 | Austedo Xr |
| Organon LLC | $17.17 | 2023 | Nexplanon |
| Shield Therapeutics INC | $16.89 | 2023 | Accrufer |
| Xeris Pharmaceuticals, INC. | $15.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.